Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 5, Issue 4, Pages e1160-e1160
Publisher
Springer Nature
Online
2014-04-10
DOI
10.1038/cddis.2014.125
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Irinotecan Synergistically Enhances the Antiproliferative and Proapoptotic Effects of Axitinib In Vitro and Improves Its Anticancer Activity In Vivo
- (2015) Bastianina Canu et al. NEOPLASIA
- Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance
- (2013) E. B. Butler et al. CANCER RESEARCH
- Role of monocarboxylate transporters in human cancers: state of the art
- (2012) Céline Pinheiro et al. JOURNAL OF BIOENERGETICS AND BIOMEMBRANES
- The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells
- (2012) Kakajan Komurov et al. Molecular Systems Biology
- New ways of assessing ovarian cancer response: metabolic imaging and beyond
- (2012) Andrea Rockall et al. CANCER IMAGING
- Mitochondrial recoupling: a novel therapeutic strategy for cancer?
- (2011) G Baffy et al. BRITISH JOURNAL OF CANCER
- Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
- (2011) Y. Zhao et al. CANCER RESEARCH
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
- (2011) J. Fruehauf et al. CLINICAL CANCER RESEARCH
- Early [18F]Fluorodeoxyglucose Positron Emission Tomography at Two Days of Gefitinib Treatment Predicts Clinical Outcome in Patients with Adenocarcinoma of the Lung
- (2011) R. Takahashi et al. CLINICAL CANCER RESEARCH
- Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non-Small Cell Lung Cancer Treated with Erlotinib
- (2011) L. Mileshkin et al. CLINICAL CANCER RESEARCH
- Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression
- (2011) Meike de Wit et al. GUT
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts
- (2010) Jochen Rössler et al. INTERNATIONAL JOURNAL OF CANCER
- Energy metabolism of leukemia cells: glycolysisversusoxidative phosphorylation
- (2010) Kazuto Suganuma et al. LEUKEMIA & LYMPHOMA
- Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
- (2010) J Rafael Sierra et al. Molecular Cancer
- Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
- (2010) Ming Zhou et al. Molecular Cancer
- Beneficial Effects of 5-Fluorouracil and Heparin-Based Portal Infusion Chemotherapy Combined with Mitomycin C and Cisplatin after Curative Resection of Pancreatic Cancer
- (2010) Koichi Aiura et al. PANCREATOLOGY
- CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models
- (2009) W Schneiderhan et al. GUT
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
- (2009) Joan H. Schiller et al. JOURNAL OF CLINICAL ONCOLOGY
- 18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization
- (2009) H. Jadvar et al. JOURNAL OF NUCLEAR MEDICINE
- Induction of Akt Activity by Chemotherapy Confers Acquired Resistance
- (2009) Wei-Chien Huang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose
- (2008) Jörg Schwarz-Dose et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started